Filing Flows › Companies › Tvardi Therapeutics › Report card
Tvardi Therapeutics earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate1 of 3 reports beat the EPS estimate
Tvardi Therapeutics (TVRD) beat the analysts' EPS estimate in 1 of its last 3 reports (33%), by -2.6% on average. Next report: Nov 12, 2026, analysts expect EPS −$0.57.
Beat rate33% of 3
Average surprise-2.6%
Next reportNov 12, 2026
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise |
|---|---|---|---|---|
| Q to Jun 2026 | Aug 14, 2026 | −$0.63 | −$0.69 | -9.3% |
| Q to Dec 2025 | Mar 31, 2026 | −$0.57 | −$0.78 | -37.3% |
| Q to Sep 2025 | Nov 13, 2025 | −$0.96 | −$0.59 | +38.7% |
Estimates and reported EPS are the Street's adjusted figures. No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
The next report: what to expect → Tvardi Therapeutics: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.